Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Accumulated Expenses (2023 - 2025)

Zenas BioPharma has reported Accumulated Expenses over the past 3 years, most recently at $13.1 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $13.1 million for Q4 2025, up 57.44% from a year ago — trailing twelve months through Dec 2025 was $13.1 million (up 57.44% YoY), and the annual figure for FY2025 was $13.1 million, up 57.44%.
  • Accumulated Expenses for Q4 2025 was $13.1 million at Zenas BioPharma, down from $45.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ZBIO hit a ceiling of $45.4 million in Q3 2025 and a floor of $3.4 million in Q1 2025.
  • Median Accumulated Expenses over the past 3 years was $13.1 million (2025), compared with a mean of $21.2 million.
  • Biggest five-year swings in Accumulated Expenses: soared 62.2% in 2024 and later soared 57.44% in 2025.
  • Zenas BioPharma's Accumulated Expenses stood at $5.1 million in 2023, then soared by 62.2% to $8.3 million in 2024, then soared by 57.44% to $13.1 million in 2025.
  • The last three reported values for Accumulated Expenses were $13.1 million (Q4 2025), $45.4 million (Q3 2025), and $44.5 million (Q2 2025) per Business Quant data.